Launch
FDA Approves First Treatment for Neurologic Symptoms of Type 3 Gaucher Disease
The Brief
- The FDA approved venglustat (brand name Infilbray) tablets.
- It is the first treatment for neurologic symptoms of type 3 Gaucher disease.
- It is approved for adults and children weighing at least 15 kg.
Why it matters
It gives clinicians the first approved option for the neurologic symptoms of type 3 Gaucher disease, a rare inherited condition that previously lacked a treatment targeting those symptoms.
Who’s affected
- clinicians treating patients with type 3 Gaucher disease
- patients and families affected by Gaucher disease
- neurologists
- #gaucher disease
- #fda approval
- #rare disease
- #neurology
- #venglustat
(MedPage Today) -- The FDA approved venglustat (Infilbray) tablets as the first treatment for neurologic symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, the agency announced Wednesday. Gaucher disease is a rare...